KRAS and non-small cell lung carcinoma: By contrast, all genes appearing in the OST panel but not in the Vantage are not druggable in the NSCLC context and only MAP2K can be targeted with selumetinib, a drug that seems to have promising efficacy in combination with docetaxel in KRAS-mutated NSCLC [39,40].